FDA approves Gomekli as first neurofibromatosis drug for adults
Merck acquisition target SpringWorks will go toe-to-toe with AstraZeneca in the US neurofibromatosis market.
Merck acquisition target SpringWorks will go toe-to-toe with AstraZeneca in the US neurofibromatosis market.
What's Your Reaction?
